Live · 12,408 China trials indexed

Know your Chinese biotech competitor before your board does.

China is now a proven biotech powerhouse. So you can keep track, TriaI-Intel can auto-track the clinical progress of your competing clinical-stage China biotechs using TrialWire.AI proprietary AI-analysis tools. Data is pulled from key trial registries, the biotech media, news announcements, and corporate websites. Unlimited searches and tracking, real-time alerts, one dashboard.

$200 / month · unlimited tracked competitors · dashboard & alerts

Scientist analyzing clinical trial data

tracked.competitors / china

Open Dashboard
AK

Akeso Inc.

Zhongshan · Bispecific Antibody

14

trials

IN

Innovent Biologics

Suzhou · mAb, ADC, GLP-1

19

trials

JU

Junshi Biosciences

Shanghai · Monoclonal Antibody

11

trials

LE

Legend Biotech

Nanjing · CAR-T

8

trials

BE

BeiGene

Beijing · Small Molecule, mAb, ADC

27

trials

last alert

Akeso · ivonescimab Phase 3 expanded to 690 pts — 2h ago

"One-third of the new drugs licensed by large US pharmaceutical companies are from China. A recent analysis shows that China now has gained parity with the US in drug development."

Science, 2026

JUST A FEW OF THE SYNCED SOURCES

ChiCTRBioSpectrum AsiaANZCTREndpoints NewsFierce BiotechChina BiotechnologyPharmaTimes China

Platform

The competitive intelligence layer for clinical-stage biotech.

Every registry, one search

Unified queries across ClinicalTrials.gov, ChiCTR and ANZCTR — with sponsor, phase, indication and site-level detail.

Auto-tracked competitors

Pin a company once. We re-scan every 6h, diff against the last snapshot, and surface what's new.

China-aware news feed

Endpoints, Fierce Biotech, BioCentury, PharmaTimes China and Yicai Global — filtered to your watchlist.

Email alerts that matter

Get an email the moment a tracked competitor opens a new site, shifts a primary completion date or hits the press.

Site-level geography

See exactly where trials are being run — country, city and investigator counts mapped at a glance.

Built for clinical teams

Magic-link sign-in, SOC2-ready hosting, audit trail of every alert delivered.

Example dashboard

5 Chinese biotechs. 79 active trials. 1 view.

A snapshot of the demo dashboard you'll get on day one — Akeso, Innovent, Junshi, Legend and BeiGene, all wired to live registry data.

Open the live dashboard
Sponsor
Study
Phase
Status
Sites
N

Akeso Inc.

NCT06532145 · ClinicalTrials.gov

Ivonescimab vs Pembrolizumab in 1L PD-L1+ NSCLC (HARMONi-6)
Phase 3
Recruiting
142
690

Innovent Biologics

ChiCTR2500098123 · ChiCTR

IBI363 (PD-1/IL-2α-bias) in Advanced NSCLC after IO Failure
Phase 2
Recruiting
18
220

Junshi Biosciences

NCT05891234 · ClinicalTrials.gov

Toripalimab + Paclitaxel/Cisplatin in Advanced ESCC
Phase 3
Active, not recruiting
67
514

Legend Biotech / J&J

NCT05985721 · ClinicalTrials.gov

Cilta-cel vs SoC in 1L Transplant-Ineligible Multiple Myeloma (CARTITUDE-5)
Phase 3
Recruiting
198
650

BeiGene

NCT06112099 · ClinicalTrials.gov

Zanubrutinib + Sonrotoclax (BGB-11417) in R/R CLL
Phase 3
Recruiting
89
410

Data sources

Built on the data clinical teams already trust.

  • ClinicalTrials.gov

    Global

  • ChiCTR

    China

  • ANZCTR

    Australia / NZ

  • WHO ICTRP

    Global

  • EU CTIS / EudraCT

    Europe

  • ISRCTN

    Global

  • jRCT

    Japan

  • FDA — Drugs@FDA

    USA

  • FDA — openFDA

    USA

  • FDA — Orange Book

    USA

  • EMA

    Europe

  • MHRA

    UK

  • PubMed / MEDLINE

    Global

  • GRID / ROR

    Global

  • NPI Registry

    USA

  • CMS Open Payments

    USA

  • CDC WONDER

    USA

  • SEER

    USA

  • GBD / IHME

    Global

  • Eurostat

    Europe

  • WHO GHO

    Global

  • US Census / ACS

    USA

  • County Health Rankings

    USA

  • BIO / Informa Phase-Transition Benchmarks

    Global

  • TransCelerate Metrics

    Global

  • SDOH Datasets

    Global

Media intelligence

More than 350 media outlets tracked in China & USA

TriaI-Intel monitors the biotech press, finance wires and local news that competitors surface in first — so you see the story before it becomes consensus. Media outlets include:

Endpoints News

USA

Fierce Biotech

USA

Fierce Pharma

USA

STAT News

USA

BioPharma Dive

USA

China Biotechnology

China

BioSpectrum Asia

Asia-Pacific

PharmaTimes China

China

Yicai Global

China

Sina Finance

China

21st Century Business Herald

China

Caixin Global

China

Plus 338+ additional outlets across English and Mandarin-language press.

Pricing

One price. Unlimited intelligence.

Professional

$200/ month

Billed monthly. Cancel anytime.

  • Unlimited tracked competitors
  • Unlimited dashboard searches
  • Auto re-scan every 6 hours
  • Email alerts on every change
  • ClinicalTrials.gov + ChiCTR + ANZCTR
  • Endpoints, Fierce, BioCentury news feed
  • Magic-link sign-in (no passwords)
Start today

STRIPE SECURE CHECKOUT · CANCEL ANYTIME

  1. 1After your secure Stripe payment you will be redirected to your secure login
  2. 2Access your Dashboard
  3. 3Add your study ClinicalTrials.Gov link or TA or therapy search terms and build your tracking Dashboard instantly

FAQ

Questions, answered.

How fresh is the data?

ClinicalTrials.gov is polled live; ChiCTR and ANZCTR snapshots refresh every 6 hours. You get an email the moment a tracked competitor changes.

Do I need a Stripe / corporate card?

Sign-in is a magic link to your work email. Billing happens through Stripe ($200/month). 

Can I add registries beyond China?

Yes — EU CTIS, Japan jRCT, India CTRI and KCT are on the roadmap. Vote in-app and we'll prioritise.